These include improved insulin sensitivity and reduced inflammation, which contribute to better overall health
The funder was not involved in the study design, collection, analysis, data interpretation and writing of the article
We note that at the August 2025 HOP Panel meeting, the HOP panel made a recommendation to create a Level 6 Neurostimulator APC
these were SUSTAIN 1, 2, 3, 6, and SUSTAIN-Japan [13,14,15, 19, 20]
A meta-analysis of eight clinical trials including ELIXA (lixisenatide), LEADER (liraglutide), SUSTAIN-6 (subcutaneous injectable semaglutide), EXSCEL (exenatide), Harmony Outcomes (albiglutide), REWIND (duraglutide), PIONEER-6 (oral administrated semaglutide) and AMPLITUDE-O (efpeglenatide) showed that GLP-1RA reduced MACE by 14% (HR 0.86, 95% CI 0.800.93) [11]
The calculated EMP from export API data was approximately $7 per 30-day course